Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia.

doi:10.1016/j.ctarc.2025.100979

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia.

Cancer treatment and research communications - 1 Jan 2025

Soeroso Noni Novisari, Syahruddin Elisna, Soliha Chaliza, Wulandari Laksmi, Setijadi Ana Rima, Ermayanti Sabrina, Pratiwi Suryanti Dwi, Infianto Andreas, Andayani Novita, Munir Sri Melati, Pratama Avissena Dutha, Kusumawardani Ida Ayu Jasminarti Dwi, Haryati Haryati, Duyan Natalie, Hanif Muhammad Alfin, Lim Darren Wan-Teck

Abstract excerpt

INTRODUCTION: Afatinib, a second-generation EGFR tyrosine kinase inhibitor (TKI), has demonstrated clinical benefit in EGFR-mutant non-small cell lung cancer (NSCLC) through clinical trials. However, real-world data, particularly in Southeast Asian populations, remain limited. This study aimed to evaluate the real-world progression-free survival (PFS) of Indonesian patients with EGFR-mutant advanced lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Afatinib

Share to Aged

Share to ErbB Receptors

Share to Indonesia

Share to Lung Neoplasms

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 40803053
DOI: 10.1016/j.ctarc.2025.100979

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia.PMID 40803053Read ↗

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.Semantic proximity Read ↗

Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.Semantic proximity Read ↗

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.Semantic proximity Read ↗

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.Semantic proximity Read ↗

Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.Semantic proximity Read ↗

Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.Semantic proximity Read ↗

Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.Semantic proximity Read ↗

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).Semantic proximity Read ↗

Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.Semantic proximity Read ↗

Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.